• Reena Khanna, Nilesh Chande, Séverine Vermeire, William J Sandborn, Claire E Parker, and Brian G Feagan.
• *Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; †Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, Ontario, Canada; ‡Division of Gastroenterology, Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium; §Division of Gastroenterology, University of California San Diego, La Jolla, California; and ‖Departments of Medicine and Epidemiology and Statistics, Western University, London, Ontario, Canada.
• Inflamm. Bowel Dis. 2016 Jul 1; 22 (7): 1737-43.

AbstractMultiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session.

31 keywords...

hide…